ENGN logo

ENGN
enGene Holdings Inc

1,162
Mkt Cap
$482.32M
Volume
95,288.00
52W High
$12.25
52W Low
$2.65
PE Ratio
-3.19
ENGN Fundamentals
Price
$7.20
Prev Close
$7.27
Open
$7.31
50D MA
$8.46
Beta
0.49
Avg. Volume
568,745.53
EPS (Annual)
-$2.29
P/B
1.71
Rev/Employee
$0.00
$206.55
Loading...
Loading...
News
all
press releases
enGene (NASDAQ:ENGN) Shares Up 5.2% - Here's Why
enGene (NASDAQ:ENGN) Stock Price Up 5.2% - Here's What Happened...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
enGene Announces Name Change to enGene Therapeutics Inc.
enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its...
Business Wire·5d ago
News Placeholder
enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Down 25.3% in March
enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 922,661...
MarketBeat·13d ago
News Placeholder
enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of "Moderate Buy" from Analysts
enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have i...
MarketBeat·17d ago
News Placeholder
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care PR Newswire VANCOUVER, BC, March 19, 2026...
PR Newswire·24d ago
News Placeholder
Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Decreases By 17.7%
enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling...
MarketBeat·26d ago
News Placeholder
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
Executives from enGene (NASDAQ:ENGN) provided an update on the company's detalimogene program in non-muscle invasive bladder cancer (NMIBC), discussing recent protocol changes, regulatory...
MarketBeat·27d ago
News Placeholder
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference
enGene (NASDAQ:ENGN) CEO Ron Cooper said the company's focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for...
MarketBeat·27d ago
News Placeholder
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update
enGene (NASDAQ:ENGN) Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company's approach to non-muscle invasive bladder cancer (NMIBC...
MarketBeat·27d ago
News Placeholder
Braidwell LP Invests $15.48 Million in enGene Holdings Inc. $ENGN
Braidwell LP purchased a new stake in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 2,266,319...
MarketBeat·28d ago
<
1
2
...
>

Latest ENGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.